摘要
采用大鼠永久性中动脉闭塞模型,研究甲磺酸胺银杏内酯B(代号:XQ-1H)对永久性局灶性脑缺血的治疗时间窗。通过观察中动脉闭塞造模后0.5,1,2,3hXQ-1H治疗给药(iv)对大鼠神经症状、脑含水量、脑梗死体积、组织形态学的影响,发现XQ-1H0.5h及1h治疗给药能使永久性局灶性脑缺血大鼠的神经行为明显改善,显著降低脑梗死率和含水量。通过测定脑组织内丙二醛(MDA)、乳酸(LD)含量以及超氧化物歧化酶(SOD)活力,显示XQ-1H0.5h及1h治疗给药,可以降低MDA及LD含量、升高SOD活力。结果表明,XQ-1H0.5及1h治疗给药对永久性局灶性脑缺血具有很好的保护作用。
In order to study the therapeutic time window of dimethylaminoethyl ginkgolide B mesylate（XQ-1H） in the permanent focal ischemia of rat,we used the rat model of the permanent middle cerebral artery occlusion（pMCAO）.Doses of 15.6,7.8 and 3.9 mg/kg of XQ-1H were intravenously administered at 0.5,1,2,3 h after MCAO,respectively.Neurological scores,infarct sizes,water contents and pathological changes in each interval were determined at 72 h after MCAO.It was observed that XQ-1H administered at 0.5 and 1 h after MCAO significantly reduced the cerebral infarct size and edema,and produced significant reductions in the neurological deficits.The protective effect of XQ-1H on the neuron cells was proved by pathological observations.In addition,the contents of MDA,lactate,and the activities of SOD were measured. Reduction in the contents of MDA and lactate and enhancement in the activities of SOD were attributed to the pretreatment of XQ-1H at 0.5 and 1 h.Our results showed that the therapeutic time window of XQ-1H extended for up to 1 h after MCAO.
出处
《中国药科大学学报》
CAS
CSCD
北大核心
2010年第2期166-170,共5页
Journal of China Pharmaceutical University
关键词
甲磺酸胺银杏内酯B
XQ-1H
局灶性脑缺血
永久性中动脉闭塞
治疗时间窗
dimethylaminoethyl ginkgolide B mesylate XQ-1H focal cerebral ischemia permanent middle cerebral artery occlusion therapeutic time window
